Concepedia

Alex Uttard

AU

Statistics

Publications

8

Citations

300

H-Index

8

Active since

2015

Affiliations

Mersana Therapeutics (United States)(Current)

Alex Uttard is an author at Mersana Therapeutics (United States) specializing in antibody-drug conjugates, pharmacology, and oncology.

ORCID

Publications per year

2015–2023

8

Publications

8

A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

Alexander V. Yurkovetskiy, Mao Yin, Natalya D. Bodyak et al. · Cancer Research · 2015 · 100 citations

, , +17

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin et al. · Molecular Cancer Therapeutics · 2021 · 75 citations · Full text

, , +17

The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy et al. · Molecular Cancer Therapeutics · 2021 · 48 citations · Full text

, , +17

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2022 · 24 citations

, , +17

Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer

D. A. Bergstrom, Natalya D. Bodyak, PU Park et al. · Cancer Research · 2016 · 17 citations

, , +17

1–5 of 8